TEL AVIV, Israel--(BUSINESS WIRE)--Cardiosonic Inc., a private company developing innovative and proprietary technology in the field of renal denervation (RDN) for the treatment of hypertension, announced the completion of the first phase of patient enrollment in its first-in-man (FIM) TIVUS I clinical study. The study is designed to collect data on the safety and performance of the TIVUS™ System, a high intensity, non-focused therapeutic ultrasound catheter system for remote tissue ablation for the treatment of hypertension by renal denervation (RDN).
